Meeting
2021 ASCO Annual Meeting
A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.
Presenter
Atish Dipankar Choudhury, MD, PhD
Dana-Farber Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03517969
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5034)
DOI
10.1200/JCO.2021.39.15_suppl.5034
Abstract #
5034
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.
Speaker: Atish Dipankar Choudhury, MD, PhD
Videos & Slides
2022 ASCO Annual Meeting
A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Speaker: Ulka N. Vaishampayan, MD
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Speaker: Ulka N. Vaishampayan, MD
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).
Speaker: James Patrick Buteau, MD FRCPC